Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.53 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15140533 | 0.86 | MET (0.60) | JAK2METALKJAK1TYK2 | |
| SCHEMBL24006750 | 0.85 | JAK2 (0.54) | JAK2METALKJAK1TYK2 | |
| SCHEMBL28380654 | 0.85 | JAK2 (0.69) | JAK2METJAK1TYK2JAK3 | |
| SCHEMBL24006736 | 0.85 | JAK2 (0.54) | JAK2METALKJAK1TYK2 | |
| SCHEMBL15140610 | 0.84 | ALK (0.58) | JAK2METALKJAK1TYK2 | |
| SCHEMBL15273697 | 0.84 | JAK2 (0.53) | JAK2METALKJAK1TYK2 | |
| SCHEMBL30228047 | 0.84 | JAK2 (0.53) | JAK2METALKJAK1TYK2 | |
| SCHEMBL2592205 | 0.84 | ALK (0.58) | JAK2METALKJAK1TYK2 | |
| SCHEMBL15273623 | 0.84 | JAK2 (0.53) | JAK2METALKJAK1TYK2 | |
| SCHEMBL2589827 | 0.81 | JAK2 (0.54) | JAK2ALKJAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916593-B2 | Alkoxy-substituted 2-aminopyridines as ALK inhibitors | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-1784396-B1 | PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, MAP3K19 | JAK2 249/4885MET 1/4885ALK 136/4885 |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, ACVR1 | JAK2 1124/4885MET 21/4885ALK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.